AI assistant
Health Catalyst, Inc. — Director's Dealing 2021
Apr 6, 2021
33681_dirs_2021-04-05_12c0c56c-dd23-4bf6-8c65-1ddd7c98eb43.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Health Catalyst, Inc. (HCAT)
CIK: 0001636422
Period of Report: 2021-04-01
Reporting Person: Llewelyn Linda (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-01 | Common Stock | M | 1100.00 | $11.78 | Acquired | 42027.00 | Direct |
| 2021-04-01 | Common Stock | M | 950.00 | $10.80 | Acquired | 42977.00 | Direct |
| 2021-04-01 | Common Stock | M | 945.00 | $11.78 | Acquired | 43922.00 | Direct |
| 2021-04-01 | Common Stock | S | 392.00 | $48.1574 | Disposed | 43530.00 | Direct |
| 2021-04-01 | Common Stock | S | 2706.00 | $47.5993 | Disposed | 40824.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-01 | Stock Option (Right to Buy) | $11.78 | M | 945.00 | Disposed | 2028-01-24 | Common Stock (945.00) | Direct |
| 2021-04-01 | Stock Option (Right to Buy) | $11.78 | M | 1100.00 | Disposed | 2028-01-24 | Common Stock (1100.00) | Direct |
| 2021-04-01 | Stock Option (Right to Buy) | $10.80 | M | 950.00 | Disposed | 2028-09-27 | Common Stock (950.00) | Direct |
Footnotes
F1: The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 9, 2020, in accordance with Rule 10b5-1.
F2: Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $48.15 to $48.16, inclusive.
F3: Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $47.10 to $47.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) and (3).
F4: 25% of the 19,999 shares underlying the options vested in an annual installment on January 24, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on January 24, 2022.
F5: 25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.